Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rocket Pharmaceuticals, Inc.    RCKT

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rocket Pharmaceuticals: 3Q Earnings Snapshot

11/04/2020 | 07:07am EST

NEW YORK (AP) _ Rocket Pharmaceuticals Inc. (RCKT) on Wednesday reported a loss of $29.1 million in its third quarter.

On a per-share basis, the New York-based company said it had a loss of 53 cents.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 46 cents per share.

Rocket Pharmaceuticals shares have climbed 29% since the beginning of the year. The stock has more than doubled in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RCKT at https://www.zacks.com/ap/RCKT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about ROCKET PHARMACEUTICALS, INC.
01/11ROCKET PHARMACEUTICALS : Announces Buildout of R&D and Manufacturing Facility to..
BU
01/07ROCKET PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8..
AQ
01/06ROCKET PHARMACEUTICALS : Announces Participation at the 39th Annual J.P. Morgan ..
BU
2020INSIDER TRENDS : Rocket Pharmaceuticals Insider Disposition Eases Back 90-Days o..
MT
2020ROCKET PHARMACEUTICALS : UBS Starts Rocket Pharmaceuticals at Buy With $75 Price..
MT
2020ROCKET PHARMACEUTICALS : Significant Insider Buying Reverses neutral Trend over ..
MT
2020ROCKET PHARMACEUTICALS : Announces Closing of Public Offering and Full Exercise ..
AQ
2020INSIDER TRENDS : 90-Day Insider Selling Trend at Rocket Pharmaceuticals Slowed w..
MT
2020ROCKET PHARMACEUTICALS : Announces Closing of Public Offering and Full Exercise ..
BU
2020ROCKET PHARMACEUTICALS : Other Events (form 8-K/A)
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -109 M - -
Net cash 2020 215 M - -
P/E ratio 2020 -27,7x
Yield 2020 -
Capitalization 3 209 M 3 209 M -
EV / Sales 2020 -
EV / Sales 2021 279x
Nbr of Employees 84
Free-Float 91,8%
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 70,50 $
Last Close Price 53,59 $
Spread / Highest target 86,6%
Spread / Average Target 31,6%
Spread / Lowest Target 4,50%
EPS Revisions
Managers and Directors
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Roderick T. Wong Chairman
Kinnari Patel Chief Operating Officer & EVP-Development
Carlos Garcia-Parada Chief Financial Officer
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.3.83%3 409
GILEAD SCIENCES, INC.16.99%85 440
WUXI APPTEC CO., LTD.36.65%68 869
VERTEX PHARMACEUTICALS2.10%62 750
REGENERON PHARMACEUTICALS13.47%57 859
BEIGENE, LTD.45.87%34 368